Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone

Seon-Jin Yoon,1,2 Junseong Park,1 Dong-Su Jang,3,4 Hyun Jung Kim,4 Joo Ho Lee,1 Euna Jo,1 Ran Joo Choi,1 Jin-Kyung Shim,1 Ju Hyung Moon,1 Eui-Hyun Kim,1 Jong Hee Chang,1 Jeong Ho Lee,5 Seok-Gu Kang1

Department of Neurosurgery,1 Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Department of Biochemistry and Molecular Biology,2 Yonsei University College of Medicine, Seoul, Korea
Medical Research Support Services,3 Yonsei University College of Medicine, Seoul, Korea
Department of Sculpture,4 Hongik University, Seoul, Korea
Graduate School of Medical Science and Engineering,5 Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
Department of Radiation Oncology,6 Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Glioblastoma (GBM) is a disease without any definite cure. Numerous approaches have been tested in efforts to conquer this brain disease, but patients invariably experience recurrence or develop resistance to treatment. New surgical tools, carefully chosen samples, and experimental methods are enabling discoveries at single-cell resolution. The present article reviews the cell-of-origin of isocitrate dehydrogenase (IDH)-wildtype GBM, beginning with the historical background for focusing on cellular origin and introducing the cancer genesis patterned on firework. The authors also review mutations associated with the senescence process in cells of the subventricular zone (SVZ), and biological validation of somatic mutations in a mouse SVZ model. Understanding GBM would facilitate research on the origin of other cancers and may catalyze the development of new management approaches or treatments against IDH-wildtype GBM.

Key Words : Cancer genesis ∙ Cell-of-origin ∙ Clock-like mutation ∙ Firework pattern ∙ Glioblastoma ∙ Subventricular zone.

INTRODUCTION

Isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) is a disease with a dismal prognosis, a distinction that has led to GBM being dubbed the “emperor of all cancers”. The disease progression is rapid, and even with standard therapy35 and supra-total resection52, the median survival of patients from diagnosis is approximately 14–20 months53,63.

There are continuing efforts by researchers in diverse disciplines, including epidemiology and molecular biology, to identify the cause of GBM. Epidemiological research on GBM suggests numerous risk factors that should be taken into account, such as irradiation of the head8,23,46,50,55 and the allergic history of patient4. Biological approaches for determining the cause of GBM include attempts to identify molecular signatures in patient samples (e.g., DNA mutations)61, the use of in vivo mouse models58, and investigation of progenitor cells of GBM13,43.
This article reviews the proof-of-concept that GBM originates in the subventricular zone (SVZ) from the microscale perspective such as a molecular biology with a cellular level resolution. The first sections present a brief overview of the disease and recapitulate the importance of mutations in the development of GBM. The remaining sections describe the cell-of-origin of GBM and the cancer genesis patterned on firework from SVZ and discuss a new hypothesis driving GBM research.

**HISTORY: PROGRESS TOWARD THE STEM CELL ORIGIN OF GBM**

There are plenty of discussions and arguments about the existence of the cell-of-origin from the early era of neuro-oncology whether the disease originates from embryonic cells or dedifferentiated cells. The brain cancer model induced from the mutation of specific cells of brain is blurring the gap between those two sides by leading an edge of this field with a subsequent drug discovery targeting GBM.

The cell-of-origin of GBM has been suspected to have characteristics of a stem cell, and this cell type has also been regarded as the source of tumor recurrence. There have been many trials conducted to isolate such treatment-resistant insidious cells from the tumor tissues and their behaviors and characteristics have been validated from multiple sources. As the patient-derived tumor cells are heterogeneous in the sample dimension (patient age, the size and location of the sample in the original tumor mass, sample control, purity of samples, or previous treatments), the mutation-induced tumor model has been accepted as another robust and predictable platform in the repeated experiments and clearly demonstrates the consequences of mutation better than the orthotopic xenograft by primary tumoursphere.

An epiphany came from the experience of 5-aminolevulinic acid (5-ALA) fluorescence without any tumor cells in the tumor specimen by pathologic examinations. During surgery to remove GBM, high fluorescence of 5-ALA was found in the walls of ventricles, which are non-coincidentally exposed after supra-total resection (or a so-called planned lobectomy). Moon et al. described interesting patterns of 5-ALA fluorescence in the ventricular wall of brain tumor patients.

What they found the most interesting was the ventricular walls with positive 5-ALA fluorescence without magnetic resonance imaging enhancement and no tumor cells in the pathology, a finding that perplexed surgeons.

Concurrence of 5-ALA positive tissues with no tumor cells in the ventricle sample helped and guided us to find the origin of GBM in the in vivo model. This 5-ALA glittering tumor negative samples from the ventricular wall or the SVZ has a pattern of mutations that has not been previously discovered. By comparing those mutation patterns, a novel way of understanding the disease could be revealed. The tumor-private mutations in the tumor tissue might facilitate the development of a new targeted therapy. In addition, the anatomical location of those cells would mature the Big Bang theory into the Firework theory of subventricular abnormal cells.

**ETIOLOGY**

Epidemiologic studies have linked a number of pollutants to the incidence of GBM. Ionizing radiation to the head at a younger age increases the risk of glioma and meningioma. An allergic or atopic disease has been associated with a lower risk of GBM, and consistently with lower-grade glioma. DNA mutations and its consequent syndromes increase the risk of acquiring GBM, such as Turcot syndrome (from mismatch repair-deficiency), Li-Fraumeni syndrome (from the germline mutation of TP53), and neurofibromatosis type 1 (from NFI gene).

However, there are additional unproven and controversial risk factors. One example is non-ionizing radiation from cellular phones. Studies have not shown a consistent increase in the risk of glioma. Another example is Radon exposure which reported to be associated with the risk of glioma in a Danish cohort, but neither radon exposure nor background radiation was associated with glioma incidence in a cohort of British children. Inconsistent results have been obtained with respect to the association of GBM development with exposure to air pollutants or particulate matter, owing in part to difficulties in measuring exposure history. There is hardly any or no evidence linking insecticides, rubber processing, pesticides, farming, solvents, metal fumes, or jet engine manufacturing to the incidence of glioma.
IDENTIFICATION OF SOMATIC MUTATIONS IN SVZ STEM CELLS

Two senescence-associated mutational patterns were found in GBM: mutational signatures 1 and 5 \(^{43}\). These two types dominated the mutation profile of SVZ samples of the astrocytic ribbon (SVZ\(^\ddagger\)) in Fig. 1A, 33\% [7.8 genes out of 23 total genes] and 45\% [10.4 genes out of 23 total genes] for signature 1 and 5 respectively in the SVZ samples\(^{43}\).

The average number of genes for mutation signature 1 jumped up from 7.8 genes (SVZ) to 81.9 genes in tumor samples of the Severance GBM cohort (10.5 fold increase)\(^{43}\). While the fold change of average number of genes that contribute to mutation signature 5 (fold 0.71, calculated from 10.4 genes of SVZ to 7.4 genes of the tumor) remains relatively stable as that of other signatures (fold 1.18, calculated from 4.8 genes of SVZ to 5.7 genes in the tumor)\(^{43}\). These findings suggest that GBM arises from the senescence process, especially if we focus on the number of genes of mutational signature 1 and 5 from SVZ to tumor, or alternatively from other causes that are associated with age.

DIRECTION OF CLONAL EVOLUTION

Accumulation of mutations in both the stem cells and the tumor region raises questions regarding the origin of the mutations. Are mutations in both tumors and SVZ related? Are they coincidental? Do mutations in the SVZ reflect contamination from the tumor? To deconvolute this complex pattern of mutations, the authors compared shared mutations (i.e., those in common to both the SVZ and tumor) and tumor-ex-
clusive mutations (i.e., those not found in the SVZ)\(^{43}\). There were several shared mutations in the tumor-free SVZ and GBM bulk tumor, including those in the \(TERT\) promoter\(^{43}\). An analysis of variant allele frequencies (VAFs) and single-cell sequencing results revealed a unidirectional pattern from SVZ to bulk tumor. A two-dimensional VAF plot in a previous report\(^{43}\) showed unique patterns of shared mutations between the tumor and the SVZ, with low-level driver mutations being located near the y-axis or tumor-axis. However, the tumor-contaminated SVZ-tumor pair showed more genes that are spread along the identity line as opposed to the uncontaminated SVZ-tumor pair\(^{43}\) (Fig. 1A).

Single-cell sequencing of the DNA of bulk tumors also validated the result showing directionality from the SVZ to the tumor\(^{43}\). Twenty-four clones were derived from one IDH-wildtype GBM patient (GBM245)\(^{43}\). The genes on the table of Lee et al.\(^{43}\) are subset of those genes of directionality. This surprising pattern of mutation was later confirmed from the intraventricular injection of plasmids to induce mutation in the SVZ\(^{16,43}\).

**PROGRESSION OF MUTATIONS IN GBM FROM THE SVZ**

Mutations oftentimes start with \(TERT\) promoter mutations in cells of the astrocytic ribbon in SVZ under the ventricle (\(TERTp\) in Fig. 1A). With additional mutations in oncogenes, the mutated cells from SVZ migrate to the cortex and manifest as the GBM (Fig. 1A, right)\(^{43}\). The authors searched for mutations in triple-matched samples of tumor-free SVZ, GBM tumor, and normal brain cortex (or blood)\(^{43}\). The authors have hypothesized that the SVZ, which includes neural stem cells, is suspected of being the origin of tumors\(^{43}\); mutations then progress from the SVZ to the tumor mass. In addition to this directionality, the number of mutations increases dramatically after the cell-of-origin reaches the cortex. As described in the previous study of Lee et al.\(^{43}\), about 20 different somatic mutations of SVZ that contribute to the mutational patterns increased to around 100 mutations in the tumor. Furthermore, mutational signature 1 dominated most mutations in tumors, whereas mutational signature 5 was preserved.
at about the same level between the SVZ and the tumor\(^{43}\). This pattern is slightly different version of the Big Bang concept and, considering the anatomic location of the progression, the authors refer to it as a “Firework” pattern (Fig. 2).

**BIOLOGICAL VALIDATION**

Deep under the ependymal layer of the SVZ is a ribbon-like feature called the astrocytic ribbon\(^ {57} \) (SVZ\(^ {2} \) in Fig. 1A). This area is populated by neural stem cells in both mouse and human brains\(^ {40} \). Using molecular techniques described below, we introduced three types of mutations into the population of cells in the SVZ. These mutation-bearing cells migrated to the cortex, ultimately forming high-grade gliomas\(^ {43} \) (Fig. 1A), presenting with firework-like GBM genesis (Fig. 2A).

A mass of GBM is created in the cortex by the mutation in the SVZ cells\(^ {43} \). Crossbred mice (postnatal day 2–3 pups) carrying LSL-tdTomato and LSL-EGFRvi8\(^ {71} \) were used for these experiments\(^ {43} \). A Cre-containing CRISPR/Cas9 plasmid was electroporated into one side of the ventricle in the brain to knock out \(Pten\) and \(Trp53\) (mouse analog of human \(TP53\) ) genes using single guide RNA (sgRNA) for these genes. After injection into the ventricular space with a sharp needle, the electroporation device was applied to deliver the plasmid into the SVZ\(^ {43} \). In the presence of the mutations, brain tumors developed in 90% of mice (9/10), with 67% of tumors developing in a region distant from the mutation-arising SVZ, and these mice showed a median survival of around 20 weeks\(^ {43} \).

Tumorigenesis, or Cancer genesis from the triple mutations marks the important step in the research of GBM\(^ {61} \). By this finding\(^ {43} \), more subtle nature of IDH-wildtype GBM can be revealed in the subsequent researches.

**HYPOTHESIS: RECURRENCE OF GBM FROM THE SVZ**

One of the next steps in the research of IDH-wildtype GBM should be related with the recurrence pattern of GBM (The hypothesis on the recurrence of GBM). Careful selection of samples without tumor in the SVZ is the beginning point of this research. Recent article by Watts group\(^ {61} \) is one example of selecting the tumor-invaded SVZ (median tumor content 22.1%, rather than tumor-free SVZ) by the IDH-wildtype GBM and its results and implications should be carefully contemplated in the research of vertical recurrence from the cell of SVZ (Fig. 2B).

GBM recurs after irradiation of tumor margins at varying depth\(^ {69} \). Although irradiating the SVZ appears to have a prognostic benefit for GBM patients\(^ {79,67} \), it does not cure these patients or prevent exacerbation of symptoms. There are at least two scenarios for recurrence of IDH-wildtype GBM. In the first case, GBM-initiating cells already present in the parenchyma of the brain restart the tumor after a dormant period (Fig. 2B, horizontal recurrence). In the second, dormant cells in the SVZ re-migrate to the tumor bed area, where they create the recurrent tumor (Fig. 1B, the only hypothesis in this article; Fig. 2B, vertical recurrence). We hope to resolve the second phenomenon using tumor-free SVZ samples from GBM patients.

**FUTURE: DEVELOPMENT OF THERAPEUTICS TARGETING THE SVZ**

Many previous attempts to treat GBM have failed and the list harbors 5-fluorouracil and methotrexate\(^ {10} \). A breakthrough in treating GBM came with the application of alkylating agents\(^ {18,62,67} \). Nitrosoureas proved the most effective at the time, and it became the most commonly used drugs for the management of brain tumors, including GBM\(^ {56,70} \). Their antitumor effects were widely accepted and even led to the development of an implantable chemotherapeutic system impregnated with the nitrosourea derivative carmustine\(^ {11} \).

However, these nitrosoureas had toxicity issues, and temozolomide subsequently gained popularity because of its limited adverse effects compared with earlier alkylating agents\(^ {9} \). But even temozolomide proved to be ineffective in treatment of recurrent GBM similarly to other alkylating agents\(^ {33,44,66} \). And the therapeutic efficacy of other novel options is limited in Bevacizumab\(^ {19,21,68} \), IDH-targeting drugs\(^ {12} \) and immunotherapy\(^ {37,40} \).

After the repeated efforts to treat the tumor itself, the origin of GBM emerged as the next generation target. Ultimately, *in vitro* and *in vivo* models will accelerate the screening for drugs that can preemptively target the initial process of cancer genesis with firework pattern from SVZ.
CONCLUSION

Mutated neural stem cells, that are present in the astrocytic ribbon in the SVZ, may migrate to the brain cortex and generate IDH-wildtype GBM with/without any molecular or environmental cue. While this concept has been demonstrated scientifically, elucidating the detailed mechanism underlying the GBM genesis process will require additional investigation. Our ongoing research efforts would focus on identifying the cell-of-origin to develop a potential treatment option for IDH–wildtype GBM, the “Emperor of cancer”.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

AUTHOR CONTRIBUTIONS

Conceptualization : SJY, JHM, EHK, JHC, JHL, SGK
Data curation : SJY, SGK
Funding acquisition : SGK
Methodology : SJY, HJK, JHL, RJC, JKS, JHL, SGK
Project administration : SGK
Visualization : SJY, DSJ, SGK
Writing - original draft : SJY, SGK
Writing - review & editing : SJY, JP, HJK, JHL, EJ, RJC, JKS, JHM, EHK, JHC, JHL, SGK

• Acknowledgements

This work was supported by grants from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI17C2586), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2019R1A2C3004155), and the NRF grant funded by the MSIP : Ministry of Science, ICT and Future Planning, Republic of Korea (NRF-2017M2A2A7A01071).

References

ness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (hl156a). Oncotarget 7 : 65543-65659, 2016


17. Filley AC, Henriquez M, Dey M: Recurrent glioma clinical trial, checkmate-143: the game is not over yet. Oncotarget 8 : 91779-91794, 2017


56. Salcman M: Survival in glioblastoma: historical perspective. Brain Tumor Pathol 35: 10-18, 2018

https://doi.org/10.3340/jkns.2019.0129